Several retrospective studies suggested that plerixafor plus G-CSF is associated with comparable or lower CD34+ cells yield, but lower risk of neutropenic fever, reduced need of antibiotics use and unscheduled hospitalization compared with cyclophosphamide plus G-CSF SD in patients with MM [78–80]. Here, CSF3 is linked to Miyoshi myopathy.